The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...
The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...
Compared with placebo, fostamatinib did not increase the number of oxygen-free days among adults hospitalized with COVID-19 and hypoxemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback